Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZ long-term extension study of mirikizumab in pediatric ulcerative colitis or Crohn's disease
MOH_2025-03-05_013903Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of mirikizumab in autoimmune colitis and Crohn's disease (6 arms), sponsored by Eli Lilly and Company. Started Jan 2025; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on MOH_2025-03-05_013903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-05_013903.